Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Ganesh Chari

Neurology Brooksville, FL Medical Doctor

NPI 1215048061 CMS profile 9439

11375 Cortez Blvd, Brooksville, FL 34613

Open in the dashboard

General payments

$713

43 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Ganesh Chari of Brooksville, FL is reported in the CMS Open Payments database as having received $713 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 40th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $23 1
2023 General $177 10
2022 General $210 13
2021 General $136 8
2020 General $56 4
2019 General $110 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ganesh Chari
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Ganesh Chari were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Ganesh Chari Neurology median Middle half National median
2019 $110 $474 $118–$2,177 $163
2020 $56 $367 $82–$2,309 $114
2021 $136 $438 $104–$2,547 $132
2022 $210 $442 $103–$2,388 $149
2023 $177 $464 $119–$2,312 $160
2024 $23 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Neurocrine Biosciences, Inc. $75 5 payments
  2. Novartis Pharmaceuticals Corporation $66 4 payments
  3. Alexion Pharmaceuticals, Inc. $62 4 payments
  4. Lilly USA, LLC $62 4 payments
  5. SK Life Science, Inc. $55 3 payments
  6. Sunovion Pharmaceuticals Inc. $42 3 payments
  7. Acorda Therapeutics, Inc $39 2 payments
  8. Biohaven Pharmaceuticals, Inc. $32 2 payments
  9. Genentech USA, Inc. $32 2 payments
  10. Kyowa Kirin, Inc. $29 2 payments
  11. Other $218 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $677 41 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23 1 payment
  3. Education $13 1 payment
Products named General payments · program years 2019–2024
  1. ULTOMIRIS $50 3 payments
  2. NURTEC ODT $50 3 payments
  3. EMGALITY $49 3 payments
  4. INGREZZA $48 3 payments
  5. Ongentys $48 3 payments
  6. INBRIJA $39 2 payments
  7. KESIMPTA Neuroscience $33 2 payments
  8. MAYZENT Neuroscience $33 2 payments
  9. KESIMPTA Neurology $33 2 payments
  10. MAYZENT Neurology $33 2 payments
  11. Other $392 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

641

Median for Neurology: 833

Drug cost

$683,057

Median for Neurology: $202,670

Branded share of claims

31.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Firdapse Amifampridine Phosphate Brand 15 $642,419
Emgality Syringe Galcanezumab-Gnlm Brand 13 $14,204
Memantine Hcl Er Memantine Hcl Brand 53 $9,398
Carbidopa-Levodopa Carbidopa/Levodopa Brand 79 $3,032
Levetiracetam Generic 58 $3,012
Pyridostigmine Bromide Generic 27 $2,520
Duloxetine Hcl Generic 21 $1,479
Carbidopa-Levodopa Er Carbidopa/Levodopa Brand 25 $1,338
Donepezil Hcl Generic 129 $1,209
Primidone Generic 66 $1,201

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$86,316

Medicare's payments for the services billed

Medicare patients

343

Average age 79

Services billed

951

208 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Ischemic heart disease 68%
Chronic kidney disease 59%
Depression 50%
Diabetes 48%
COPD 48%
Heart failure 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record